Streetbeat News

Partnerships

CCLD

Kovo HealthTech Corporation, a company specializing in healthcare billing and coding services, has announced a partnership with CareCloud, a provider of cloud-based healthcare IT solutions. The partnership aims to integrate Kovo HealthTech's billing and coding services with CareCloud's electronic health records (EHR) platform. This collaboration is expected to enhance the efficiency and effectiveness of healthcare providers' operations by streamlining their billing processes and improving the management of patient records.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:03 pm

AZN

Allorion Therapeutics has entered into an agreement with AstraZeneca for the development and global commercialization of an EGFR L858R allosteric inhibitor, aimed at treating advanced EGFR-Mutant NSCLC. AstraZeneca has an exclusive option to license this inhibitor. Allorion could receive up to $40 million in upfront and near-term payments, over $500 million in milestone payments, and royalties on worldwide net sales.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:02 pm

SNES

SenesTech has announced an expansion of its distribution with Pesterminators to include the deployment of its product Evolve. This expansion also extends Pesterminators' territory into the United Arab Emirates (UAE).

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:02 pm

NVS

VYGR

Voyager Therapeutics' stock is up following the announcement of a strategic collaboration and capsid license agreement with Novartis for gene therapies targeting Huntington's disease and spinal muscular atrophy.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:58 pm

VFS

VinFast Auto Ltd (NASDAQ:VFS), a Vietnamese EV maker, has signed agreements with five dealerships in the U.S. to sell its electric vehicles, starting with the VF 8 SUV. The company plans to expand its U.S. dealer network to 125 locations and currently operates 13 stores in California. Despite this expansion, VFS shares dropped by 4.78% to $7.97 in premarket trading.

Portfolio Pulse from Shivani Kumaresan

January 02, 2024 | 1:52 pm

NRXP

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) will present a keynote address on ketamine's efficacy and risks for treating suicidal depression at the Sachs Neuroscience Innovation Forum. The company plans to file a New Drug Application for ketamine in 2024 in the US and EU. NRx has shown ketamine's superiority to placebo and non-inferiority to electroshock therapy in trials. They are developing a new formulation with Nephron Pharmaceuticals and a REMS program. NRx has created HOPE Therapeutics, Inc. to advance ketamine's development and will award rights to shareholders and new investors. NRx is also developing NRX-101 for suicidal bipolar depression and chronic pain, in partnership with Alvogen Pharmaceuticals.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:45 pm

CLSK

LBPH

MARA

RIOT

VYGR

Longboard Pharmaceuticals (LBPH) reported positive topline data from its PACIFIC 1b/2a clinical trial of Bexicaserin, with a 53.3% median seizure reduction compared to 20.8% for the placebo group. Voyager Therapeutics (VYGR) announced a capsid license agreement and strategic collaboration with Novartis for gene therapy advancement. Crypto-related stocks like Marathon Digital Holdings (MARA), Riot Blockchain (RIOT), and CleanSpark (CLSK) saw an uptick as Bitcoin's value surpassed $45,000.

Portfolio Pulse from ryanfaloona@benzinga.com

January 02, 2024 | 1:42 pm

IINN

Inspira Technologies (NASDAQ:IINN) has signed a non-binding Letter of Intent with Northwestern Memorial Hospital for the clinical use of its INSPIRA ART100 device, pending FDA clearance. The collaboration will involve Northwestern purchasing disposables for the device and providing usage data to Inspira Technologies. The agreement is contingent on FDA approval expected in the first half of 2024 and a definitive evaluation agreement.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:37 pm

GOOG

GOOGL

Alphabet Inc.'s Google Bard, a ChatGPT rival, is seeking user feedback for its 2024 wishlist. Requests include a standalone app, integration with Google Assistant, reduced censorship, fewer hallucinations, and persistent memory. Google is already working on Assistant integration, announced during the Pixel launch in Oct. 2023. A standalone app could benefit iOS users since Google Assistant isn't pre-installed on iOS devices. Persistent memory would help in tasks like debugging code or writing extended texts. Google Bard aims to compete with ChatGPT by adding consumer-facing features.

Portfolio Pulse from Rounak Jain

January 02, 2024 | 1:27 pm

CC

IFF

TROX

Wall Street's most accurate analysts recommend holding three materials stocks with over 3% dividend yields: The Chemours Company (CC), Tronox Holdings plc (TROX), and International Flavors & Fragrances Inc. (IFF). JP Morgan and Morgan Stanley analysts have adjusted their ratings and price targets for CC, with recent weaker-than-expected quarterly results. TROX was downgraded by JP Morgan and upgraded by Credit Suisse, following a 26% decrease in third-quarter revenue. IFF's partnership with Kemira was expanded, and analysts from Stifel and JP Morgan have updated their price targets.

Portfolio Pulse from Avi Kapoor

January 02, 2024 | 1:09 pm